Big3Bio provides recaps for events in the SFBay region, from major partnering/investor meetings to private forums and discussions. Check out all of the event recaps by Big3Bio correspondents here.
NOTE: Scroll event info via your BROWSER SCROLLBAR (do not use mouse wheel)
The PODD teams bring to the West Coast a Drug Delivery Design & Partnering Meeting This inaugural program focuses on meeting the design needs
The PODD teams bring to the West Coast a Drug Delivery Design & Partnering Meeting
This inaugural program focuses on meeting the design needs of drug delivery systems from the perspectives of pharma, physicians, patients, investors, as well as KOLs in personalized medicine and digital.
may 21 (Monday) - 22 (Tuesday)
InterContinental Mark Hopkins
999 California St, San Francisco, CA 94108
Speakers: Matthew Wright (Genentech), Vahid Zia (Gilead), Simon Wong (Genentech), Eugene Chen (Genentech), Jaochim Rudolph (Genentech), John Link (Gilead), Fabio Broccatelli (Genentech), Bernard Murray (Gilead) Organizers: Matthew Wright (Genentech) Date: 5/22/2018 Time: 8:45-17:00 Registration
Speakers: Matthew Wright (Genentech), Vahid Zia (Gilead), Simon Wong (Genentech), Eugene Chen (Genentech), Jaochim Rudolph (Genentech), John Link (Gilead), Fabio Broccatelli (Genentech), Bernard Murray (Gilead)
Organizers: Matthew Wright (Genentech)
Registration fee (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0;
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Catalent Pharma Solutions; Worldwide Clinical Trials
Vendor show vendors registered to date: (7)Absorption Systems; Celerion; Foster Delivery Science; Pion Inc.; Plexxikon Inc; Quotient Clinical Ltd; Seventh Wave
Registration deadline:5/21/2018 (it will close sooner if the seating cap is reached)
About the Topic
Poor exposure following oral administration is a common challenge facing discovery programs and consequently a frequent focus for DMPK scientists. Frequently, potent compounds cannot be further developed due to less-than-ideal ADME (absorption, distribution, metabolism, and excretion) properties that prevent the compounds to be available following oral administration. Beyond the discovery phase the importance of understanding and optimizing oral exposure continues in the preclinical and ultimately clinical phases of drug development. Inadequate oral exposure could be due to suboptimal physicochemical properties, or problems in absorption from the gut, or first-pass metabolism in the gut and liver, or high intrinsic clearance of the compounds.
The focus of this workshop/symposium is on: 1) to identify and learn about the issues that contribute to low oral exposure, 2) to discuss approaches that one could use to overcome those challenges, 3) to present additional methodologies that can aid in solving exposure problems and 4) to provide suggestions on how to work with partners in Medicinal Chemistry and Biological Sciences within Project Teams.
This workshop/symposium will cover the following topics:
- Pharmacokinetic concepts – absorption, bioavailability, and clearance factors contributing to low oral exposure
- Physiological factors that affect oral exposure
- Physicochemical factors that influence oral exposure
- Metabolism-based issues that give rise to poor oral exposure
- Transporter-based issues that give rise to poor oral exposure
- How to identify the source of problem in oral exposure – properties of the molecules or conditions of the experiment?
- Biopharmaceutical Aspects of oral drug exposure
- Approaches to overcome oral exposure issues, including case studies
- Enabling Exposure of ADME Challenged compounds
- What do Medicinal Chemists/Biologists want and how can we work with them
8:45 – 8:50am PBSS Welcome M. Wright
8:50 – 9:25am 1. Pharmacokinetic Concepts (Matthew Wright)
9:25 – 10:00 am 2. Absorption of Drugs from the GI Tract (Vahid Zia)
10:00 – 10:20am Major Sponsor Presentation Worldwide Clinical Trials
10:20 – 10:35am Break
10:35 – 11:20pm 3. Metabolism-based issues in oral bioavailability (Simon Wong)
11:20 – 12:00 pm 4. Transporter-based issues in oral bioavailability (Eugene Chen)
12:00 – 1:00pm Lunch
1:00 – 1:45 pm 1. Enabling Technologies to achieve oral exposure (Jaochim Rudolph)
1:45 – 2:30 pm 2. Working in non-Lipinski Space – Discovery of GS-5885 (Ledipasvir) (John Link)
2:30 – 2:45pm Major Sponsor Presentation Vendor name TBD
2:45 – 3:00pm Break
3:00 – 3:45pm 3. In silico applications (Fabio Broccatelli)
3:45 – 4:00 pm Break
4:00 – 4:45pm 4. Characterization and differentiation of apparently metabolically stable compounds (Bernard Murray)
4:45 – 5:00pm Wrap-up (Matthew Wright)
All Day (Tuesday)
Crowne Plaza Hotel
San Francisco Airport - Burlingame
Researchers and leaders from academia, hospitals, government and industry gather for two days at Stanford Medicine to spark collaborations, address challenges, and identify actionable steps for using large-scale data analysis and
Researchers and leaders from academia, hospitals, government and industry gather for two days at Stanford Medicine to spark collaborations, address challenges, and identify actionable steps
for using large-scale data analysis and technology to improve human health.
By harnessing the vast datasets of biomedical information now available to us, we envision a world in which we can prevent disease before it strikes and cure it decisively if it does. This is the power of Precision Health. To predict, prevent, and cure disease — precisely.
Precision Health is a fundamental shift to more proactive and personalized health care that empowers people to lead healthy lives. It is in this spirit of possibility and promise that Stanford Medicine will be hosting the sixth year of this conference, bringing together international researchers and leaders from academia, health care, government, and industry to develop actionable steps for improving human health.
may 23 (Wednesday) - 24 (Thursday)